Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

被引：888

作者：

Cook, David ^{[1
]}

Brown, Dearg ^{[1
]}

Alexander, Robert ^{[2
]}

March, Ruth ^{[1
]}

Morgan, Paul ^{[1
]}

Satterthwaite, Gemma ^{[1
]}

Pangalos, Menelas N. ^{[1
]}

机构：

[1] AstraZeneca, Innovat Med & Early Dev, Macclesfield SK10 4TG, Cheshire, England

[2] AstraZeneca, Innovat Med & Early Dev, Cambridge, MA 02139 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2014年 / 13卷 / 06期

关键词：

RESEARCH-AND-DEVELOPMENT; NONVALVULAR ATRIAL-FIBRILLATION; THROMBIN INHIBITOR AZD0837; PLACEBO-CONTROLLED TRIAL; VITAMIN-K ANTAGONISTS; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; RECEPTOR ANTAGONIST; PROSTAGLANDIN D-2; DEVELOPMENT PRODUCTIVITY;

D O I：

10.1038/nrd4309

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Maintaining research and development (R& D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor-the right culture-is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R& D teams, and although it is too early to demonstrate whether this has improved the company's R& D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.

引用

页码：419 / 431

页数：13

共 71 条

[1] Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression [J].

aan het Rot, Marije ;

Collins, Katherine A. ;

Murrough, James W. ;

Perez, Andrew M. ;

Reich, David L. ;

Charney, Dennis S. ;

Mathew, Sanjay J. .

BIOLOGICAL PSYCHIATRY, 2010, 67 (02) :139-145

[2]

Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690

[3]

Albers GW, 2003, LANCET, V362, P1691

[4]

[Anonymous], J CLIN ONCOL S

[5]

[Anonymous], 2010, TOXICOL

[6]

Arimura A, 2001, J PHARMACOL EXP THER, V298, P411

[7] Phase II and Phase III attrition rates 2011-2012 [J].

Arrowsmith, John ;

Miller, Philip .

NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (08) :568-568

[8] A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma [J].

Barnes, N. ;

Pavord, I. ;

Chuchalin, A. ;

Bell, J. ;

Hunter, M. ;

Lewis, T. ;

Parker, D. ;

Payton, M. ;

Collins, L. Pearce ;

Pettipher, R. ;

Steiner, J. ;

Perkins, C. M. .

CLINICAL AND EXPERIMENTAL ALLERGY, 2012, 42 (01) :38-48

[9] Antidepressant effects of ketamine in depressed patients [J].

Berman, RM ;

Cappiello, A ;

Anand, A ;

Oren, DA ;

Heninger, GR ;

Charney, DS ;

Krystal, JH .

BIOLOGICAL PSYCHIATRY, 2000, 47 (04) :351-354

[10] Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients [J].

Busse, William W. ;

Wenzel, Sally E. ;

Meltzer, Eli O. ;

Kerwin, Edward M. ;

Liu, Mark C. ;

Zhang, Nan ;

Chon, Yun ;

Budelsky, Alison L. ;

Lin, Joseph ;

Lin, Shao-Lee .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) :339-345

← 1 2 3 4 5 6 7 8 →